tbuckley/cabot-search huggingface dataset:
Abstract 4534: Beneficial Effects of Autologous Bone Marrow Cell Infusion in Patients with Chronic Critical Limb Ischemia
Authors: Claudio Napoli, Bartolomeo Farzati, Vincenzo Sica, Andrea Silvestroni, Giuseppe Coppola, Emanuele Iannuzzi, Francesco Cacciatore, Francesca Mazzella, Anna Florio, Angelo Matarazzo
Journal: Circulation (2008)

Short-term (within 6 weeks follow up) clinical studies indicate that implantation of bone marrow cells (BMCs) into ischemic limbs may improve peripheral ischemia. Here, the long-term safety and feasibility of intrarterial autologous BMCs with oral treatment with antioxidants and L-arginine was investigated in patients with critical ischemia due to advanced atherosclerotic peripheral arterial disease (PAD). The investigation was conformed with the Declaration of Helsinki. We obtained written informed consent from all patients and the Medical Ethics Committee of II University of Naples School of Medicine approved the protocol (March 2005). Moreover, we notified this study to the Italian Ministery of Health and to the NIH-controlled trial register ( NCT00306085 ). 18 patients with PAD (advanced III/IV Fontaine stages) were enrolled in this study. An additional group of 18 patients taking maximal drug therapy that refused BMC therapy served as control. The BMC-treated group received two doses of BMCs in the leg arteries (time 0 and 45 days). After 30 days from the first BMC dose, patients received daily antioxidants, and L-arginine. Therapeutic neoangiogenesis was estimated by angiography and laser Doppler\capillaroscopy. Ankle brachial index improvement (ΔABI: &gt;0.1) was seen in 10 patients at 3 months and in 12 patients at 12–18 months. Ischemic ulcers improved in 13 patients (after 6 –12 months). Although 2 underwent amputation, the mean maximum walking distance significantly increased at 3 months and was sustained up to 18 months. Among conservative patients, 10 underwent amputation in comparison to 2 BMC-treated patients. Despite some small published studies employing BMC with a short follow up in PAD patients, we provide the first evidence of long-term safety and feasibility of intrarterial autologous BMC infusion and cotreatment with antioxidants and L-arginine in patients with advanced atherosclerotic PAD. Patients received both BMCs and metabolic treatment to maximize the effect of vitamin E and L-arginine. Results showed significant improvements in the ABI, ulcer healing, maximum walking distance, microcirculation blood flow, and reduction of amputation risk, without any serious adverse reactions until 18 months.
Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Authors: C. Alfaro Autor, M. Soriano, R. Gómez Bravo, M. Méndez García, A. Royuela, A. Cruz-Bermudez, J.M. García, V. Calvo de Juan, F. Franco, M. Provencio
Journal: Annals of Oncology (2019)
Determinants of Circulating Tumor DNA Levels across Lymphoma Histologic Subtypes
Authors: Joseph G Schroers-Martin, David M. Kurtz, Joanne Soo, Michael Jin, Florian Scherer, Alexander Craig, Jacob J Chabon, Chih Long Liu, Henning Stehr, Ulrich Duehrsen, Andreas Hüttmann, Anne Ségolène Cottereau, Michel Meignan, Olivier Casasnovas, Jason R. Westin, Gianluca Gaidano, Davide Rossi, Ranjana H. Advani, Mark Roschewski, Wyndham H. Wilson, Maximilian Diehn, Ash A. Alizadeh
Journal: Blood (2017)
A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN); A result of dose escalation cohort
Authors: N. Ngamphaiboon, C. Jiarpinitnun, T. Siripoon, S. Lukerak, A. Jinawath, N. Jinawath, L. Arsa, J. Konmun, N. Kongsuphon, N. Sankaseam, E. Sirachainan, P. Witoonpanich, A. Kositwattanarerk, P. Pattaranutaporn
Journal: Annals of Oncology (2019)
Capecitabine +best supportive care (BSC) or erlotinib +BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT)
Authors: B. Kataria, A. Sharma, S. Mishra, S. Bhatnagar, S. Thulkar, M. Yadav, R.K. Sahoo, R. Pramanik, C.P. Prasad, V. Sreenivas, M.K. S
Journal: Annals of Oncology (2019)
Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line
Authors: Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti
Journal: Clinical and Molecular Hepatology (2019)

Background/Aims Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term sorafenib treatment, lowering its effectiveness. Hence, it is important to overcome drug resistance to improve overall management of HCC. Here, we have identified a candidate biomarker for sorafenib resistance in a HCC model cell line, HepG2. Methods Initially, comparative proteomic profiling of parental HepG2 [HepG2 (P)] and sorafenib-resistant HepG2 [HepG2 (R)] cells was performed via MALDI (matrix-assisted laser desorption/ionization) which revealed the deregulation of vimentin in HepG2 (R) cells. Gene and protein level expression of vimentin was also observed through quantitative real-time polymerase chain reaction (qRT PCR) and fluorescence-activated cell sorting (FACS), respectively. Furthermore, withaferin A was used to study regulation of vimentin expression and its significance in sorafenib resistance. Results Both gene and protein level of vimentin expression was found to be downregulated in HepG2 (R) in comparison to HepG2 (P). Interestingly, the study demonstrated that withaferin A further lowered the expression of vimentin in HepG2 (R) cells in a dose-dependent manner. Also, inhibition of vimentin lowered ABCG2 expression and decreased cell viability in parental as well as sorafenib resistant HepG2 cells. Conclusions Hence, our study for the first time highlighted the probable therapeutic potential of vimentin in sorafenib resistant HepG2, a HCC model cell line. Keywords: Carcinoma, Hepatocellular; Sorafenib resistance; Vimentin; Withaferin A
Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial
Authors: H.L. McArthur, J.H.S. Leal, D.B. Page, A. Bardia, L. Spring, C.D. Abaya, R.K. Basho, L. Ristow, H. Coleman, S. Shiao, S. Knott, M. Tighiouart, F. Dadmanesh, S. Verma, A. Giuliano
Journal: Annals of Oncology (2019)
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
Authors: G. Zalcman, J. Mazieres, L. Greillier, S. Brosseau, S. Lantuejoul, P. Do, O. Bylicki, I. Monnet, R. Corre, C. Audigier-Valette, M. Locatelli-Sanchez, O. Molinier, F. Guisier, T. Urban, D. Planchard, C. Ligeza-Poisson, E. Amour, F. Morin, D. Moro-Sibilot, A. Scherpereel
Journal: Annals of Oncology (2019)
Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)
Authors: S. Knispel, M. Gassenmaier, A.M. Menzies, C. Loquai, D.B. Johnson, C. Franklin, R. Gutzmer, J.C. Hassel, C. Weishaupt, T. Eigentler, P. Schummer, F. Kiecker, C. Owen, M.I. Schmidgen, K.C. Kähler, C.G. Cann, D. Niebel, P. Mohr, D. Schadendorf, L. Zimmer
Journal: Annals of Oncology (2019)
The gut microbiome and metabolic syndrome
Authors: Kruttika Dabke, Gustaf Hendrick, Suzanne Devkota
Journal: Journal of Clinical Investigation (2019)

The metabolic syndrome (MetS) is a constellation of risk factors that, if left untreated, will often progress to greater metabolic defects such as type 2 diabetes and nonalcoholic fatty liver disease. While these risk factors have been established for over 40 years, the definition of MetS warrants reconsideration in light of the substantial data that have emerged from studies of the gut microbiome. In this Review we present the existing recent literature that supports the gut microbiome's potential influence on the various risk factors of MetS. The interplay of the intestinal microbiota with host metabolism has been shown to be mediated by a myriad of factors, including a defective gut barrier, bile acid metabolism, antibiotic use, and the pleiotropic effects of microbially produced metabolites. These data show that events that start in the gut, often in response to external cues such as diet and circadian disruption, have far-reaching effects beyond the gut.
Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): Real world data from 2 university hospitals in Spain
Authors: J.F. Cordoba Ortega, A. Gasol Cudos, S. Morales Murillo, O. Pallise, M.A. Salud Salvia, J. Brunet Vidal, H. Pla Juher, A. Carbó Bagué, R. Porta Balanya, A. Izquierdo Font, A. Hernández Martínez, A. Franquesa, J. Bosch-Barrera, E.S. Girona
Journal: Annals of Oncology (2019)
Obstetric and maternal outcome of 134 patients with Hodgkin lymphoma diagnosed during pregnancy: Results from the INCIP registry
Authors: F. Amant, C. Maggen, D. Dierickx, E. Lugtenburg, A. Laenen, E. Cardonick, R.G. Shmakov, M. Bellido Casado, A.C. Garcia, M. Gziri, M. Halaska, P. Ottevanger, K. Van Calsteren, A. L’Hauglin, E. Polushkina, L. Van Dam, P. Vandenberghe, S.H. Woei-A-Jin
Journal: Annals of Oncology (2019)
Interim results from trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumours
Authors: J. Wang, M. Barve, E. Chiorean, P. LoRusso, K. Courtney, D. Qi, J. Bullington, M. Sardone, J. Chen, C. Brooks, S. Shemesh, T.M. Bauer
Journal: Annals of Oncology (2019)
A Prospective, Randomized Study of Melphalan, Prednisone, Lenalidomide (MPR) versus Melphalan (200 Mg/M2) and Autologous Transplantation (Mel200) in Newly Diagnosed Myeloma Patients: An Interim Analysis.
Authors: Antonio Palumbo, Federica Cavallo, Dina Ben Yehuda, Paola Omedè, Agostina Siniscalchi, Maide Cavalli, Barbara Lupo, Aaron Polliack, Izhar Hardan, Fabiana Gentilini, Paolo Corradini, Claudia Crippa, Fausto Rossini, Francesca Patriarca, Annalisa Citro, Alessandro Petrucci, Angelo Michele Carella, Giulia Benevolo, Tommaso Caravita, Francesco Di Raimondo, Mario Boccadoro
Journal: Blood (2009)
Phase I/II clinical trials for relapsed elderly acute leukemia patients: Importance of performance status at re-induction. A single center retrospective experience
Authors: W. J. Van Heeckeren, P. Fu, P. Barr, M. Laughlin, W. Tse, H. Lazarus, S. Remick, B. Cooper
Journal: Journal of Clinical Oncology (2006)

6575 Background: Relapsed/refractory acute leukemia patients (pts) have a poor outcome and should be considered for enrollment on clinical trials. Elderly (≥ 60 yr) acute leukemia patients often are excluded from phase I/II cytotoxic agent re-induction chemotherapy trials due to concerns for treatment-related toxicity. Methods: Pts with relapsed/refractory acute leukemia who were enrolled on three consecutive phase I/II clinical trials at University Hospitals of Cleveland were evaluated for outcome data including complete response (CR), serious adverse events, and overall survival (OS). Outcome data was compared for pts age ≥ 60 yr versus &lt; 60 yr. Pts with ECOG Performance Status (PS) 0 to 3 were eligible and there was no age limitation. Results: Between 1994 and 11/2005, 96 acute leukemia pts median age 60 yr (range 19–78) were enrolled: 29 pts received phase I topotecan-etoposide; 31 pts received phase I fludarabine, carboplatin, and topotecan (FCT); and 37 pts received phase II FCT plus thalidomide. In univariate analysis, PS at therapy initiation, mean # prior treatments, and disease status at time of treatment were not statistically different between older and younger pts ( Table ). Using Kaplan-Meier method, early treatment-related mortality and OS were similar in pts age ≥ 60 yr compared to pts &lt; 60 yr ( Table ). Mean # ≥ grade 3 toxicities and CR also were similar in both groups ( Table ). In univariate (p = 0.001) and multivariate (p = 0.0004) analyses by Cox modeling, pts PS 0–1 had better OS than PS 2–3 (PS 0–1: 30-day survival 98% and 1 yr survival 24% versus PS 2–3: 30-day survival 81% and 1 yr survival 6%). Conclusions: Poor PS is an important negative predictor of outcomes in relapsed/refractory acute leukemia pts. Advanced age should not exclude pts from cytotoxic re-induction chemotherapy trials. [Table: see text] No significant financial relationships to disclose.
First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma
Authors: Y.Y. Janjigian, S. Maron, J.F. Chou, A.R. Gabler, M.Z. Simmons, P. Momtaz, M. Shcherba, G.Y. Ku, E. Won, F. Sanchez-Vega, H. Gerdes, D.P. Kelsen, D.H. Ilson, D. Solit, N. Schultz, P.M. Shah, M. Capanu, J.F. Hechtman, M. Lamendola-Essel
Journal: Annals of Oncology (2019)
Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Authors: Y.-S. Lu, A. Bardia, R.V. Vázquez, M.A. Colleoni, P. Wheatley-Price, Y.-H. Im, G. Babu, D. Tripathy, B.R. Lanoue, D. Chandiwana, A. Ridolfi, G. Hughes, J.P. Zarate, I. Gounaris, N. Harbeck
Journal: Annals of Oncology (2019)
Chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): Quality of Life (QoL) results from the GO2 phase III trial
Authors: P. Hall, D. Swinson, S. Lord, C. Handforth, D. Cairns, H. Marshall, R. Petty, M. Bennett, G. Velikova, M.T. Seymour
Journal: Annals of Oncology (2019)
Recent developments and highlights in immune monitoring of allergen immunotherapy
Authors: Menno C. van Zelm, Craig I. McKenzie, Nirupama Varese, Jennifer M. Rolland, Robyn E. O'Hehir
Journal: Allergy (2019)

Abstract Allergic diseases are the most common chronic immune‐mediated disorders and can manifest with an enormous diversity in clinical severity and symptoms. Underlying mechanisms for the adverse immune response to allergens and its downregulation by treatment are still being revealed. As a result, there have been, and still are, major challenges in diagnosis, prediction of disease progression/evolution and treatment. Currently, the only corrective treatment available is allergen immunotherapy (AIT). AIT modifies the immune response through long‐term repeated exposure to defined doses of allergen. However, as the treatment usually needs to be continued for several years to be effective, and can be accompanied by adverse reactions, many patients face difficulties completing their schedule. Long‐term therapy also potentially incurs high costs. Therefore, there is a great need for objective markers to predict or to monitor individual patient's beneficial changes in immune response during therapy so that efficacy can be identified as early as possible. In this review, we specifically address recent technical developments that have generated new insights into allergic disease pathogenesis, and how these could potentially be translated into routine laboratory assays for disease monitoring during AIT that are relatively inexpensive, robust and scalable.
A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL)
Authors: S. Sahebjam, E. Le Rhun, P. Queirolo, G. Jerusalem, D. Subramaniam, M. Bear, Z. Yang, Y. Chen, P.F. Conte
Journal: Annals of Oncology (2019)
Randomised efficacy and safety results for atezolizumab (Atezo) + bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Authors: M. Lee, B.-Y. Ryoo, C.-H. Hsu, K. Numata, S. Stein, W. Verret, S. Hack, J. Spahn, B. Liu, H. Abdullah, R. He, K.-H. Lee
Journal: Annals of Oncology (2019)
Abstract 40: Tissue Oximetry During Out-of-Hospital Cardiopulmonary Resuscitation
Authors: Adam Frisch, Rachel Frank, Brian Suffoletto, Christian Martin-Gill, James Menegazzi, Clifton Callaway
Journal: Circulation (2012)

Introduction: Coronary perfusion pressure is a common surrogate marker for myocardial perfusion and the effectiveness of CPR. Peripheral perfusion is far less studied. We sought to evaluate tissue oxygen saturation (StO 2 ) as a surrogate marker for peripheral perfusion during CPR and after return of spontaneous circulation (ROSC) during out-of-hospital cardiac arrest (OOHCA). Methods: This study was approved by our IRB. EMS physicians responded to cases of cardiac arrest and placed a continuous near infrared tissue oximeter on the thenar eminence of the patient to measure StO 2 , which was recorded continuously during the resuscitation. Each case was then broken down into 30-second epochs classified as ongoing CPR or post-ROSC. The mean StO 2 for each epoch was calculated. A two-sample T test was used to compare the two conditions. Results: 16 patient encounters were analyzed with a total of 390 epochs, 175 with pulses and 215 during CPR. Patients ranged in age from 34-88 and 10 were male (62.5%). The StO 2 average for the epochs during CPR was 50.04 (SD 18.5) and 66.74 (24.6) after ROSC in patients with pulses. A difference of 16.7 was seen between the two conditions (p&lt;0.001). Conclusion: In this cohort of patients, there was a lower average StO 2 reading in patients with CPR being performed when compared to the post ROSC group. While the cause of this difference may be multifactorial, lower tissue oxygen saturation may imply worse peripheral perfusion. Future studies will need to evaluate the cause of this difference and potential impacts it may have on cardiac arrest outcome in the prehospital setting.
A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS)
Authors: M.A. Davies, J.S. Weber, K.T. Flaherty, G.A. McArthur, M.B. Reddy, A. Golden, J.L. Culbertson, C.T. Thomas, H.A. Tawbi, G.V. Long
Journal: Annals of Oncology (2019)
ClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Authors: G.K. Abou-Alfa, T. Macarulla Mercade, M. Javle, R.K. Kelley, S. Lubner, J. Adeva, J.M. Cleary, D.V. Catenacci, M.J. Borad, J.A. Bridgewater, W.P. Harris, A.G. Murphy, D.-Y. Oh, J. Whisenant, B. Wu, L. Jiang, C. Gliser, S.S. Pandya, J.W. Valle, A.X. Zhu
Journal: Annals of Oncology (2019)
Ring-like uptake appearance on dedicated breast positron emission tomography before chemotherapy predicts outcome of neoadjuvant chemotherapy in breast cancer
Authors: N. Masumoto, T. Kadoya, M. Nishina, Y. Kimura, A. Amioka, T. Itagaki, S. Sasada, A. Emi, M. Okada
Journal: Annals of Oncology (2019)
A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
Authors: J. Llovet, K.V. Shepard, R.S. Finn, M. Ikeda, M. Sung, A.D. Baron, M. Kudo, T. Okusaka, M. Kobayashi, H. Kumada, S. Kaneko, M. Pracht, K. Mamontov, T. Meyer, K. Mody, T. Kubota, K. Saito, A.B. Siegel, L. Dubrovsky, A.X. Zhu
Journal: Annals of Oncology (2019)
Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
Authors: Kroopa Joshi, Marc Robert de Massy, Mazlina Ismail, James L. Reading, Imran Uddin, Annemarie Woolston, Emine Hatipoglu, Theres Oakes, Rachel Rosenthal, Thomas Peacock, Tahel Ronel, Mahdad Noursadeghi, Virginia Turati, Andrew J. S. Furness, Andrew Georgiou, Yien Ning Sophia Wong, Assma Ben Aissa, Mariana Werner Sunderland, Mariam Jamal-Hanjani, Selvaraju Veeriah, Nicolai J. Birkbak, Gareth A. Wilson, Crispin T. Hiley, Ehsan Ghorani, José Afonso Guerra-Assunção, Javier Herrero, Tariq Enver, Sine R. Hadrup, Allan Hackshaw, Karl S. Peggs, Nicholas McGranahan, Charles Swanton, Sergio A. Quezada, Benny Chain
Journal: Nature Medicine (2019)
Effect of a Novel Transition Program on Disability After Stroke
Authors: Emily Somerville, Brittany Minor, Marian Keglovits, Yan Yan, Susan Stark
Journal: JAMA Network Open (2019)

<h3>Importance</h3> A gap in care for stroke survivors exists at the point of transition from inpatient rehabilitation to home, when survivors encounter new environmental barriers because of the cognitive and sensorimotor sequelae of stroke. Resolving these barriers and improving independence in the community have the potential to significantly improve stroke survivors' long-term morbidity. <h3>Objective</h3> To investigate the efficacy and safety of a novel enhanced rehabilitation transition program to reduce environmental barriers and improve daily activity performance and community participation among stroke survivors. <h3>Design, Setting, and Participants</h3> This is a phase 2b, single-blind, parallel-group, randomized clinical trial. Participants will be randomized using a 1:1 allocation ratio, stratified by Functional Independence Measure and age, to either attentional control or the intervention. Community Participation Transition After Stroke (COMPASS) is a complex intervention that uses 2 complementary evidence-based interventions: home modifications and strategy training delivered in the home. Community participation after stroke, measured by the Reintegration to Normal Living Index, is the primary outcome. Secondary outcomes include quality of life after stroke, measured by the Stroke Impact Scale, and daily activity performance and magnitude of environmental barriers in the home, both measured by the In-Home Occupational Performance Evaluation. An intention-to-treat analysis will be used. A total of 180 participants, who are 50 years or older, were independent in activities of daily living prior to stroke, and are undergoing inpatient rehabilitation following stroke with a plan to be discharged home, will be included in the study. <h3>Discussion</h3> Stroke is a leading cause of serious long-term disability in the United States. The COMPASS study is ongoing. To date, 99 participants have been recruited and 77 randomized, with 37 in the treatment group and 40 in the control group. Resumption of previous activities immediately after discharge can improve immediate and long-term community participation. Results from this study will fill a critical gap in stroke rehabilitation evidence by providing important information about the long-term community participation and daily activity performance among stroke survivors as well as environmental barriers in their homes. <h3>Trial Registration</h3> ClinicalTrials.gov identifier:NCT03485820
The BRIGHTLIGHT national survey of the impact of specialist teenage and young adult cancer care on caregivers’ information and support needs
Authors: R.M. Taylor, A. Martins, J. Alvarez-Galvez, L.A. Fern, C. Vindrola-Padros, J.A. Barber, F. Gibson, J. Whelan
Journal: Annals of Oncology (2019)
Primary results of multicenter phase II study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PII)
Authors: A. Miki, H. Satake, T. Watanabe, N. Tanaka, K. Hirata, K. Shimozaki, H. Tanioka, M. Matsuura, T. Kyogoku, M. Tatsumi, K. Matoba, Y. Oka, S. Adachi, H. Yasui, M. Kotaka, T. Kato, A. Tsuji
Journal: Annals of Oncology (2019)
Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)
Authors: M.S. Van der Heijden, N. van Dijk, L. Smit, K. Hendricksen, J.M. de Feijter, E. Bekers, E. Hooijberg, C.C.N. van Rooijen, A. Broeks, Y. Lubeck, K. Sikorska, T.N. Schumacher, P. Kvistborg, T. Boellaard, C.U. Blank, B.W. van Rhijn
Journal: Annals of Oncology (2019)